Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

Comment by mba123ccuon Feb 10, 2022 8:50am
52 Views
Post# 34415818

RE:BIOV CLOSES 1ST TRANCHE OF PVT PLCMNT/2,680 MLNS UNITS/.15

RE:BIOV CLOSES 1ST TRANCHE OF PVT PLCMNT/2,680 MLNS UNITS/.15
Humanist wrote: BIOVAXYS CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENT

BioVaxys Technology Corp. 
Feb 10, 2022, 02:37 ET
VANCOUVER, BC, Feb. 10, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the first tranche ("Tranche 1") of its previously annunced non-brokered private placement (the "Private Placement"). Pursuant to Tranche 1 of the Private Placement, the Company has issued 2,680,000 units ("Units") at a price of $0.15 per Unit for gross proceeds of $402,000. Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant (a "Warrant"). Each Warrant is exercisable for one additional Common Share at an exercise price of $0.30 for a period of 36 months.

The aggregate Private Placement consists of the sale of up to 6,666,667 Units for total gross proceeds of up to approximately $1,000,000. Closing of the second tranche of the Private Placement is anticipated to complete within the next week.

All securities issued pursuant to Tranche 1 of the Private Placement are subject to a statutory hold period of four months and one day from the date of issuance. The Company paid no finders fees in connection with the closing of Tranche 1. The Company intends to use the net proceeds of the Private Placement for working capital.
 



Well there's some working capital to continue doing R&D but I hope there is other good news soon.
<< Previous
Bullboard Posts
Next >>